AstraZeneca PLC (AZN) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 19/100
- 10Y CAGR
- 9%
- Median YoY
- 8.6%
- YoY volatility
- σ 16.7pp· uneven
- Quarters ≥ 20%
- 6 of 40
- Negative quarters
- 8
- Valuation vs own 10Y history
- P/S 4.2x · 10Y median 4.7x · 29th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 6 of 40 → 6 of 40 pts
- Steadiness (typical swing 16.7pp) → 13.1 of 25 pts
- Pace (median 8.6% YoY) → 0 of 20 pts
- Latest quarter (6.4% YoY) → 0 of 15 pts
- Score: 19 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 9% | 8.6% | 16.7pp | 6 of 40 | 8 |
| EPSEPS | 11.4% | 5.2% | 139.5pp | 16 of 35 | 15 |
| Op cash flowOperating cash flow | 15.9% | 14.1% | 291.3pp | 18 of 38 | 16 |
| EBITDAEBITDA | 10.8% | 9.6% | 37.2pp | 16 of 40 | 13 |
| FCFFree cash flow | 32.1% | 26.3% | 652.8pp | 17 of 31 | 13 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: AZN on the compounders surface · All compounders, ranked